Acceder

Farmas USA

135K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
10.489 / 17.006
#83907

Re: Farmas USA

NVAX

Que ganas tengo de verla cerca de mi precio señorrrrrrr. Que te voy a contar a tí...

#83908

Re: Farmas USA

Novavax, Inc.

Novavax is already making preparations to commercialize its Respiratory Syncytial Virus (RSV) vaccine in the elderly since management anticipates positive top-line Phase 3 data this summer. In light of this positive outlook, analyst Heather Behanna of Wedbush recommends buying shares of the company during the recent market pullback and ahead of the pivotal data release.

The analyst explains, “Although there is inherent risk in commercializing the first RSV vaccine, we believe the flu vaccine sets a clear path forward.” In the flu season of 2014-2015, 67% of the elderly population received flu vaccines, according to CDC data. Behanna explains that the elderly population regularly visits physicians and are advised to get vaccinated.”

Behanna notes that potential commercialization success for the vaccine rests upon the recommendations from the Advisory Committee on Immunization Practices (ACIP). The analyst explains that the recommendation is only given to approved products, but Novavax is already working with the CDC and gathering relevant research to “begin a dialogue and to educate the ACIP on the need for RSV vaccination.” Ideally, Novavax’s RSV vaccine will launch ahead of the 2018 flu season.

Based on the positive outlook for the company’s RSV vaccine in the elderly, Behanna reiterated an Outperfrom rating on Novavax with a $14 price target on February 16. According to TipRanks, four other analysts currently has a buy rating on Novavax.

 

http://blog.tipranks.com/2016/02/biotech-insights-analysts-bullish-on-novavax-inc-nvax-and-neuralstem-inc-cur/

#83910

Re: Farmas USA

Jeje, al final entraste a porta gayola. Suerte! Yo estoy pensando poner todos los huevos en la misma cesta. Quito órden HZNP y pongo órden en NVAX a 5$. Paso de intras.

#83912

Re: Farmas USA

NVAX sigo expectante ......cuanto más se distancie de los 4 mejor para todos....y eso requiere cerrar hoy por encima de 5....y nuestro querido IBB por encima de 260...

Te puede interesar...

- No hay entradas a destacar -

- No hay entradas a destacar -